UCB S.A. UNSP.ADR 1/2 - Asset Resilience Ratio
UCB S.A. UNSP.ADR 1/2 (UNC0) has an Asset Resilience Ratio of 1.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how UCB S.A. UNSP.ADR 1/2's Asset Resilience Ratio has changed over time. See UNC0 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down UCB S.A. UNSP.ADR 1/2's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see UCB S.A. UNSP.ADR 1/2 stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €196.00 Million | 1.08% |
| Total Liquid Assets | €196.00 Million | 1.08% |
Asset Resilience Insights
- Limited Liquidity: UCB S.A. UNSP.ADR 1/2 maintains only 1.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
UCB S.A. UNSP.ADR 1/2 Industry Peers by Asset Resilience Ratio
Compare UCB S.A. UNSP.ADR 1/2's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
INVENTIVA ADS/1 O.N.
F:6IVA |
Biotechnology | 52.73% |
|
Medincell SA
PA:MEDCL |
Biotechnology | 45.63% |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS |
Biotechnology | 65.79% |
Annual Asset Resilience Ratio for UCB S.A. UNSP.ADR 1/2 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for UCB S.A. UNSP.ADR 1/2.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.08% | €196.00 Million ≈ $229.14 Million |
€18.16 Billion ≈ $21.23 Billion |
+0.02pp |
| 2024-12-31 | 1.06% | €184.00 Million ≈ $215.12 Million |
€17.35 Billion ≈ $20.28 Billion |
-0.19pp |
| 2023-12-31 | 1.25% | €195.00 Million ≈ $227.98 Million |
€15.54 Billion ≈ $18.17 Billion |
-0.28pp |
| 2022-12-31 | 1.53% | €243.00 Million ≈ $284.09 Million |
€15.87 Billion ≈ $18.55 Billion |
+0.04pp |
| 2021-12-31 | 1.49% | €212.00 Million ≈ $247.85 Million |
€14.21 Billion ≈ $16.61 Billion |
-- |
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more